In the BioHarmony Drug Report Database

"Preview" Icon

Fampridine

Ampyra, Fampyra (dalfampridine) is a small molecule pharmaceutical. Dalfampridine was first approved as Ampyra on 2010-01-22. It is used to treat multiple sclerosis and neurologic gait disorders in the USA. It has been approved in Europe to treat multiple sclerosis. It is known to target potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily D member 1, potassium voltage-gated channel subfamily D member 2, transient receptor potential cation channel subfamily V member 2, inward rectifier potassium channel 13, potassium voltage-gated channel subfamily A member 10, potassium voltage-gated channel subfamily C member 1, potassium voltage-gated channel subfamily B member 2, potassium voltage-gated channel subfamily D member 3, and potassium voltage-gated channel subfamily A member 5.

 

Trade Name

 

Fampyra
 

Common Name

 

dalfampridine
 

ChEMBL ID

 

CHEMBL284348
 

Indication

 

multiple sclerosis, neurologic gait disorders
 

Drug Class

 

Image (chem structure or protein)

Fampridine structure rendering